Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-31

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

NCT05681234

Liver Carcinoma

COMPLETED NA

Clinical Study of 18F-FAPI-RGD in Breast Tumors

NCT05976620

Breast Tumors

COMPLETED

To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT

NCT06205888

Tumour

NOT_YET_RECRUITING

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

NCT07023848

Breast Cancer Gastric Cancer (GC) Urothelial Carcinoma (UC)

ENROLLING_BY_INVITATION EARLY_PHASE1

18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study

NCT02938546

Non-small-cell Lung Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Stage II Breast Cancer Stage III Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[18F]SF-DEVD-2

Group Type EXPERIMENTAL

[18F]SF-DEVD-2

Intervention Type DRUG

Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2

[18F]-FDG

Intervention Type DRUG

Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]SF-DEVD-2

Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2

Intervention Type DRUG

[18F]-FDG

Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients voluntarily signed informed consent;
2. Age18-70, male or female;
3. Diagnosed with stage 2 or 3 breast cancer
4. Solid tumors、masses larger than 2cm with lymph node metastasis
5. Pathology is HER3+、triple negative patients
6. Patients to be treated with neoadjuvant chemotherapy

Exclusion Criteria

1. Age greater than or equal to 70 years old
2. Abnormal liver and kidney function (more than five times the normal value)
3. Diagnosis level of breast cancer stage 4 or second time tumor patients

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No